Nature to aid open access

Nature Publishing Group will begin depositing manuscripts into PubMed Central six months after publication on behalf of authors, starting later this summer, according to a release. But some open access publishing advocates say this is just a way for the publisher to maintain an embargo period, rather than making content immediately available. Earlier this year the National Institutes of Health linkurl:issued a mandate;http://www.the-scientist.com/blog/display/54028/ that required all biomedical

Written byAndrea Gawrylewski
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share
Nature Publishing Group will begin depositing manuscripts into PubMed Central six months after publication on behalf of authors, starting later this summer, according to a release. But some open access publishing advocates say this is just a way for the publisher to maintain an embargo period, rather than making content immediately available. Earlier this year the National Institutes of Health linkurl:issued a mandate;http://www.the-scientist.com/blog/display/54028/ that required all biomedical research papers sponsored by NIH funds to be deposited in PubMed Central within 12 months of publication. Many publishing groups have linkurl:objected;http://www.the-scientist.com/blog/display/54442/ to this mandate, saying that it violates their copyrights and publishing models. David Hoole, head of content licensing and brand marketing at Nature, told The Scientist that the free service is meant to help authors comply with the NIH mandate. Authors will decide whether to have Nature deposit for them into PubMed Central during the article submission process. Nature has assembled a team of about half a dozen people, including a new head of author services, to manage the PubMed Central submissions, and Hoole said they are devoting significant resources to make sure it's done right. But some open access advocates question Nature's motives. The purpose of this new service is to "lock in [Nature's] embargo," Stevan Harnad, cognitive scientist at the University of Southampton, UK, and vocal open access supporter, told The Scientist. Nature is hoping, he added, that if given the choice, authors will choose the convenience of letting Nature deposit for them after six months, rather than take the time to do it themselves immediately. "We believe that the top level journals operate better under a subscription model rather than free publication model," Hoole said. "The six-month embargo protects a subscription model, more than a zero [cost] model does." During the six-month embargo, people still have to pay to read Nature content. Authors should not need the convenience of having someone else deposit for them into PubMed Central, Harnad added. His group calculated that it only takes six minutes on the authors' parts to deposit final, peer-reviewed papers in PubMed Central. Some institutions, like Harvard University, have linkurl:adopted their own mandates,;http://www.the-scientist.com/blog/display/54301/ requiring authors to deposit accepted manuscripts into a university repository immediately. In the case of Harvard, Nature offered to help them populate their repository but Harvard refused to accept Nature's six-month embargo, Hoole said. So authors getting published in Nature have gotten exemptions from their university to submit to the institutional repository.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Graphic of amino acid chains folded into proteins

Expi293™ PRO Expression System: Higher Yields Across a Wider Variety of Proteins

Thermo Fisher Logo